D R Budman

Summary

Affiliation: North Shore University Hospital
Country: USA

Publications

  1. doi request reprint The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center, North Shore Univ Hospital, Lake Success, NY 11042, USA
    Invest New Drugs 29:1224-9. 2011
  2. pmc Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center, Lake Success, NY 1104, USA
    Anticancer Drugs 23:272-9. 2012
  3. ncbi request reprint New directions with capecitabine combinations in advanced breast cancer
    Daniel R Budman
    Division of Medical Oncology, New York University, Medical College, North Shore University Hospital, Manhasset 11030, USA
    Oncology (Williston Park) 16:23-8. 2002
  4. ncbi request reprint In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Breast Cancer Res Treat 74:41-6. 2002
  5. ncbi request reprint Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset, NY 11030, USA
    Anticancer Drugs 13:1011-6. 2002
  6. ncbi request reprint The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression
    Daniel R Budman
    Division of Medical Oncology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA
    Cancer Invest 20:38-44. 2002
  7. ncbi request reprint Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, NY 11030, USA
    Anticancer Drugs 15:877-81. 2004
  8. ncbi request reprint Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, 11030, USA
    Oncology 70:147-53. 2006
  9. ncbi request reprint Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis
    D R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Cancer Chemother Pharmacol 47:525-31. 2001
  10. ncbi request reprint Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis
    Daniel R Budman
    Experimental Therapeutics Section, Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, NY, USA
    Anticancer Drugs 17:921-8. 2006

Collaborators

Detail Information

Publications48

  1. doi request reprint The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center, North Shore Univ Hospital, Lake Success, NY 11042, USA
    Invest New Drugs 29:1224-9. 2011
    ..These effects are cytotoxic and not cytostatic. As all these agents are used clinically, we have identified combinations which warrant further investigation...
  2. pmc Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center, Lake Success, NY 1104, USA
    Anticancer Drugs 23:272-9. 2012
    ..The triplet of panobinostat with either doxorubicin/carboplatin or gemcitabine/carboplatin was especially potent in all cell lines. As all these agents are clinically available, further studies of the potent combinations are warranted...
  3. ncbi request reprint New directions with capecitabine combinations in advanced breast cancer
    Daniel R Budman
    Division of Medical Oncology, New York University, Medical College, North Shore University Hospital, Manhasset 11030, USA
    Oncology (Williston Park) 16:23-8. 2002
    ..Continued evaluation of capecitabine combinations will help to define the roles of this valuable agent, the only oral fluoropyrimidine for treatment of breast cancer available in the United States...
  4. ncbi request reprint In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Breast Cancer Res Treat 74:41-6. 2002
    ....
  5. ncbi request reprint Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset, NY 11030, USA
    Anticancer Drugs 13:1011-6. 2002
    ..Combinations of docetaxel with platinum or etoposide may lead to subadditive effects in treatment...
  6. ncbi request reprint The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression
    Daniel R Budman
    Division of Medical Oncology, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA
    Cancer Invest 20:38-44. 2002
  7. ncbi request reprint Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, NY 11030, USA
    Anticancer Drugs 15:877-81. 2004
    ..As the toxicity of LY 293111 in man is not hematological, this agent may have a role in combination therapy of selected malignancies...
  8. ncbi request reprint Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, 11030, USA
    Oncology 70:147-53. 2006
    ..To identify synergistic combinations of clinically available agents with zoledronic acid which would enhance antitumor activity as measured by median effect isobologram analysis and apoptosis assays in vitro...
  9. ncbi request reprint Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis
    D R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Cancer Chemother Pharmacol 47:525-31. 2001
    ..In this phase I trial in humans the safety and pharmacology of LY309887 on a weekly schedule combined with daily oral 5-mg doses of folic acid were evaluated...
  10. ncbi request reprint Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis
    Daniel R Budman
    Experimental Therapeutics Section, Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, NY, USA
    Anticancer Drugs 17:921-8. 2006
    ..These experiments suggest further studies of the dual kinase inhibitor with selected cytotoxics such as 5'-deoxy-5-fluorouridine are warranted...
  11. ncbi request reprint Capecitabine
    D R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Invest New Drugs 18:355-63. 2000
    ..Further study is needed to determine whether capecitabine has a broader spectrum of action thus affecting other tumor types than 5-fluorouracil. Major dose limiting toxicities have been hand foot syndrome, nausea/vomiting, and diarrhea...
  12. ncbi request reprint A phase I study of sequential vinorelbine followed by paclitaxel
    D R Budman
    Don Monti Division of Oncology, Department of Medicine, North Shore University Hospital, New York University School of Medicine, Manhasset, USA
    Ann Oncol 10:861-3. 1999
    ..A phase I dose escalation trial of vinorelbine daily x 3 with paclitaxel on day 3 repeated every 28 days in metastatic breast cancer patients was completed...
  13. ncbi request reprint Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro
    Daniel R Budman
    Section of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center of North Shore University Hospital New York University, 450 Lakeville Road, New York, Lake Success 11040, USA
    Breast Cancer Res Treat 104:93-101. 2007
    ..The combination of fluvastatin or another inhibitor of prenylation and trastuzumab may be attractive for clinical development as the effect of trastuzumab in Her2/neu positive breast tumors is incomplete as a single agent...
  14. ncbi request reprint Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B
    D R Budman
    Department of Medicine, North Shore University Hospital New York University School of Medicine, Manhasset 11030, USA
    J Natl Cancer Inst 90:1205-11. 1998
    ..The Cancer and Leukemia Group B study 8541 examined the effects of adjuvant treatment using conventional-range dose and dose intensity in female patients with stage II (axillary lymph node-positive) breast cancer...
  15. ncbi request reprint Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine
    D R Budman
    Department of Medicine, North Shore University Hospital, New York University Medical College, Manhasset 11030, USA
    J Clin Oncol 16:1795-802. 1998
    ....
  16. ncbi request reprint Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B
    D R Budman
    Cancer and Leukemia Group B, Chicago, IL, USA
    J Clin Oncol 15:3275-9. 1997
    ....
  17. ncbi request reprint Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
    W Kreis
    Don Monti Division of Oncology, Department of Medicine, North Shore University Hospital, New York University School of Medicine, Manhasset, USA
    Ann Oncol 10:33-8. 1999
    ..To determine the optimal dosage and the toxicities of these two agents for future trials...
  18. ncbi request reprint Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study
    W Kreis
    Don Monti Division of Oncology, Department of Medicine, North Shore University Hospital, Cornell University Medical College, Manhasset, New York 11030
    Leukemia 5:991-8. 1991
    ..62% whereas TBC was significantly lower (p less than 0.001) for Ara-U than for Ara-C (3.02 versus 20.48 l/h/m2)...
  19. ncbi request reprint Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours
    W Kreis
    Department of Medicine, North Shore University Hospital, Cornell University Medical College, Manhasset, New York
    Cancer Res 48:1337-42. 1988
    ..Toxicity of this combination was predominantly confined to bone marrow and gastrointestinal toxicity...
  20. pmc Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells
    X M Liu
    Don Monti Division of Medical Oncology, North Shore University Hospital, NYU School of Medicine, Manhasset, New York 11030, USA
    Br J Cancer 85:1403-11. 2001
    ..1 microM of vinorelbine or paclitaxel, this protein may serve as an early indicator of apoptosis induced not only by DNA damaging agents, but also by antimicrotubule drugs...
  21. ncbi request reprint Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin
    J H Marsh
    Don Monti Division of Oncology Hematology, Department of Medicine, North Shore University Hospital, Manhasset, NY 11030
    Cancer Chemother Pharmacol 31:481-4. 1993
    ..ARA-C levels were not significantly changed in comparison with those obtained in a prior study of ARA-C with THU (ARA-C plasma levels at 3 h, 2630 +/- 1170 ng/ml)...
  22. ncbi request reprint Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP)
    S M Lichtman
    Don Monti Division of Medical Oncology, Department of Medicine, North Shore University Hospital--New York University School of Medicine, Manhasset, New York 11030, USA
    Am J Clin Oncol 24:360-2. 2001
    ..The median survival was 26 months. Hematologic and nonhematologic toxicity was tolerable. We believe that TNOP is an excellent therapeutic option in this group of elderly patients, particularly in the palliative setting...
  23. ncbi request reprint In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
    D R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset 11030, USA
    Leukemia 15:1517-20. 2001
    ....
  24. pmc Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells
    X M Liu
    Department of Medicine, Division of Medical Oncology, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1129, New York, NY 10029, USA
    Br J Cancer 89:1566-73. 2003
    ..Exposure of AI cells to paciltaxel followed by vinorelbine produced synergism. Our data, thus, provide a basis for the synergistic combination of vinorelbine and paclitaxel for the treatment of advanced prostate cancer...
  25. ncbi request reprint A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents
    W Kreis
    Don Monti Division of Oncology, North Shore University Hospital, Manhasset, NY 11030, USA
    Cancer Chemother Pharmacol 47:78-82. 2001
    ..Several of the synergistic combinations which are not mediated by the MDR pump need to be tested in vivo for efficacy...
  26. doi request reprint Implications of applied research for prognosis and therapy of breast cancer
    M F Barginear
    Don Monti Division of Medical Oncology Division of Hematology, North Shore University Hospital, New York University School of Medicine, United States
    Crit Rev Oncol Hematol 65:223-34. 2008
    ..These are leading to a paradigm shift from empirical treatment to an individually tailored approach, which may soon become a realistic option for patients, based on specific molecular profiles...
  27. ncbi request reprint A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine
    Samit Hirawat
    Don Monti Division of Oncology, Department of Medicine, North Shore University Hospital New York University, Manhasset, New York 11030, USA
    Cancer Invest 25:148-53. 2007
    ..Irinotecan and capecitabine have a broad spectrum of activity in human malignancy and are synergistic in an animal model when irinotecan precedes capecitabine...
  28. ncbi request reprint Capecitabine-docetaxel combination treatment
    Julia Mandelblat
    New York University, Don Monti Division of Oncology, North Shore University Hospital, Manhasset, New York, USA
    Expert Rev Anticancer Ther 6:1169-78. 2006
    ..Combination treatments may be preferable to sequential therapy for patients requiring urgent reduction in their tumor burden. Combinations of cytotoxic agents in combination with biological agents are currently being defined...
  29. doi request reprint In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia
    Anthony Calabro
    Experimental Therapeutics Section, Don Monti Division of Oncology, Monter Cancer Center, Lake Success, NY 11042, USA
    Anticancer Drugs 19:705-12. 2008
    ..These effects were independent of whether or not human plasma was used in the assay system. These studies suggest several novel combinations of agents that need to be evaluated in the management of leukemia...
  30. doi request reprint Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia
    Steven L Allen
    North Shore University Hospital, Albert Einstein College of Medicine, Monter Cancer Center, 450 Lakeville Road, Lake Success, NY 11042, United States
    Leuk Res 34:487-91. 2010
    ..Between both trials responses occurred in 9/20 patients with secondary AML. Both trials demonstrated an acceptable safety profile and significant antileukemic activity in patients with poor-risk AML, especially those with secondary AML...
  31. doi request reprint Emerging role of small ribonucleic acids in gastrointestinal tumors
    Iuliana Shapira
    Hematology Oncology, Hofstra University School of Medicine, Monter Cancer Center, 450 Lakeville Road, Lake Success, NY 11042, USA
    Crit Rev Oncol Hematol 76:173-85. 2010
    ..The distinct physiology of small RNAs may translate in more targeted cancer therapies in the near future...
  32. ncbi request reprint Dose and schedule as determinants of outcomes in chemotherapy for breast cancer
    Daniel R Budman
    Don Monti Division of Oncology, North Shore University Hospital, New York University, Manhasset, NY 11030, USA
    Semin Oncol 31:3-9. 2004
    ..Consequently, treatment practices should use both dose intensity and dose compression to increase the likelihood of positive outcomes in patients with breast cancer...
  33. ncbi request reprint The heat shock protein 90 chaperone complex: an evolving therapeutic target
    M F Barginear
    Don Monti Division of Oncology, North Shore University Hospital of New York University, New York 11042, USA
    Curr Cancer Drug Targets 8:522-32. 2008
    ..We review the current clinical status of therapeutic efforts to perturb this pathway and discuss future directions...
  34. ncbi request reprint Heparin-induced thrombocytopenia complicating hemodialysis
    M F Barginear
    Don Monti Division of Medical Oncology Division of Hematology, North Shore University Hospital, New York University School of Medicine, New York 11042, USA
    Clin Appl Thromb Hemost 14:105-7. 2008
    ..The authors report a patient with renal failure and calciphylaxis who developed HIT after starting hemodialysis. She was successfully treated with Argatroban...
  35. doi request reprint The hedgehog pathway as a therapeutic target for treatment of breast cancer
    M F Barginear
    The Breast Cancer Medicine Program at the Tisch Cancer Institute, The Mount Sinai School of Medicine, New York, NY, USA
    Breast Cancer Res Treat 116:239-46. 2009
    ..Here we review Hh signaling, advances in small molecule and antibody-based inhibitors targeting the Hh pathway, and dysregulation of the Hh signaling pathway in breast cancer...
  36. ncbi request reprint The androgen receptor: structure, mutations, and antiandrogens
    Samit Hirawat
    Don Monti Division of Medical Oncology Division of Hematology, Department of Medicine, North Shore University Hospital NYU School of Medicine, Manhasset, New York, USA
    Cancer Invest 21:400-17. 2003
    ..Future research focuses on the development of drugs directed at suppressing the androgen drive of the androgen sensitive clone of the tumor and making the nonsensitive subset more susceptible to cytotoxics...
  37. doi request reprint Adjuvant chemotherapy for early breast cancer in the elderly
    Mary Leung
    Don Monti Division of Oncology, Monter Cancer Center, New York University, 450 Lakeville Road, Lake Success, NY 11042, USA
    Curr Treat Options Oncol 10:144-58. 2009
    ..Studies specifically for patients over 65 years of age are urgently needed in this population to provide evidence-based proof of the current approach...
  38. ncbi request reprint Review: tubulin function, action of antitubulin drugs, and new drug development
    Federico Pellegrini
    Experimental Therapeutics Section, Don Monti Division of Oncology, North Shore University Hospital, New York University School of Medicine, Manhasset, New York 11030, USA
    Cancer Invest 23:264-73. 2005
    ..Agents that interfere with the motor protein kinesin are entering clinical trials...
  39. ncbi request reprint Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    J Clin Oncol 23:5365-73. 2005
    ..LY293111 has antineoplastic activity in a variety of preclinical models. The tolerability and pharmacokinetics of LY293111 administered continuously, by mouth, BID for repeat cycles of 21 days was evaluated...
  40. ncbi request reprint WTH3, a new member of the Rab6 gene family, and multidrug resistance
    Jidong Shan
    Department of Molecular Oncology, North Shore Long Island Jewish Health System, New York University School of Medicine, R132 Research Building, 350 Community Drive, Manhasset, NY 11030, USA
    Biochim Biophys Acta 1589:112-23. 2002
    ..Flow cytometry and fluorescence microscope experiments suggest that the WTH3 transgene stimulated the host's uptake and retention of DOX. Our results imply that the WTH3 gene plays a role(s) in MDR phenotype development in vitro...
  41. doi request reprint Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review
    Brian H Kim
    Monter Cancer Center, North Shore LIJ Health System, New York University School of Medicine, Lake Success, NY, USA
    Oncology 76:231-8. 2009
    ..We report the 5-year incidence of hypersensitivity to oxaliplatin in our clinical program, the patient and disease characteristics associated with its occurrence, and review the literature...
  42. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  43. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  44. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  45. ncbi request reprint Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869
    Anthony J Guidi
    North Shore Medical Center, Salem, MA, USA
    J Clin Oncol 20:732-42. 2002
    ..However, the utility of this assay in node-positive patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) has not been well studied...
  46. ncbi request reprint Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer
    Jianping Guo
    Department of Radiation Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
    Int J Cancer 121:1296-305. 2007
    ..Multivariate analysis demonstrated that SNCG was a strong independent prognostic variable. SNCG is a new unfavorable prognostic marker for breast cancer progression and a potential target for breast cancer treatment...
  47. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  48. ncbi request reprint Therapeutic index, tubulin binders, and clinical medicine
    Daniel R Budman
    Cancer Invest 23:479-80. 2005